Abstract
Introduction: Sudden sensorineural hearing loss (SSNHL) is an otological emergency requiring prompt treatment. Intratympanic steroid therapy delivers a high concentration of steroid directly into the inner ear while minimizing systemic adverse effects. Despite its routine use, outcomes of intratympanic methylprednisolone therapy have not been documented in our setting. This study evaluated its therapeutic effect in SSNHL patients treated in routine clinical practice.
Methods: This hospital-based prospective observational analytical study was conducted in the Department of ENT at Lumbini Medical College from June 2025 to May 2026. Forty patients with SSNHL who received intratympanic methylprednisolone (40 mg in 1 mL) as part of routine care were included. Each received four injections over 15 days. Hearing thresholds were assessed using pure tone audiometry before treatment and at one month after treatment, using 3-frequency (500, 1000, 2000 Hz) and 4-frequency (500, 1000, 2000, 4000 Hz) averages. Improvement was defined as a hearing gain of ≥10 dB in the 3-frequency PTA.
Results: Improvement was observed in 35 patients (87.5%). The mean 3-frequency PTA improved from 60.3 ± 6.6 dB to 49.8 ± 10.2 dB (mean gain 10.4 ± 7.8 dB; p < 0.001). The mean 4-frequency PTA improved from 62.0 ± 6.0 dB to 52.3 ± 9.9 dB (mean gain 9.7 ± 6.5 dB; p < 0.001). No vertigo, perforation, or infection occurred.
Conclusions: Intratympanic methylprednisolone therapy resulted in significant hearing improvement in patients with SSNHL treated in routine clinical practice, with a favorable safety profile.
References
1. Kleyn AD. Sudden complete or partial loss of function of the octavus-system in apparently normal persons. Acta Otolaryngol. 1944;32(5–6):407–429. https://doi.org/10.3109/00016484409119921
2. Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg. 2019;161(1_suppl):S1–S45. PMID: https://pubmed.ncbi.nlm.nih.gov/31369359/. https://doi.org/10.1177/0194599819859885
3. Rai S, Koirala K, Sherpa P. Effectiveness of early treatment with steroids in outcome of sudden sensorineural hearing loss: a study from Western Nepal. Nepalese J ENT Head Neck Surg. 2018;5(2):5–7. https://doi.org/10.3126/njenthns.v5i2.19403
4. Zhao D, Tong B, Wang Q, Hellstrom S, Duan M. A comparison of effects of systemic and intratympanic steroid therapies for sudden sensorineural hearing loss: a meta-analysis. J Otol. 2016;11(1):18–23. PMID: https://pubmed.ncbi.nlm.nih.gov/29937806/. https://doi.org/10.1016/j.joto.2016.02.002
5. Kepekci A. Effect of intratympanic steroid therapy in sudden sensorineural hearing loss: our clinical experience. Med Sci Int Med J. 2024;13(4):861. https://doi.org/10.5455/medscience.2024.08.093
6. Kennedy DJ, Williams E, Wolf L, et al. Intratympanic steroid administration and predictors of recovery in sudden sensorineural hearing loss. PLoS One. 2025;20(10):e0332809. PMID: https://pubmed.ncbi.nlm.nih.gov/41066339/. https://doi.org/10.1371/journal.pone.0332809
7. Margolis RH, Eikelboom RH, Johnson C, Ginter SM, Swanepoel DW, Moore BCJ. False air-bone gaps at 4 kHz in listeners with normal hearing and sensorineural hearing loss. Int J Audiol. 2013;52(8):526–532. PMID: https://pubmed.ncbi.nlm.nih.gov/23713469/. https://doi.org/10.3109/14992027.2013.792437
8. Suzuki H, Hashida K, Nguyen KH, Hohchi N, Katoh A, Koizumi H, Ohbuchi T. Efficacy of intratympanic steroid administration on idiopathic sudden sensorineural hearing loss in comparison with hyperbaric oxygen therapy. Laryngoscope. 2012;122(5):1154–1157. PMID: https://pubmed.ncbi.nlm.nih.gov/22447636/. https://doi.org/10.1002/lary.23245
9. Haynes DS, O'Malley M, Cohen S, Watford K, Labadie RF. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope. 2007;117(1):3–15. PMID: https://pubmed.ncbi.nlm.nih.gov/17202923/. https://doi.org/10.1097/01.mlg.0000245058.11866.15
10. Berjis N, Soheilipour S, Musavi A, Hashemi SM. Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss. Adv Biomed Res. 2016;5:111. PMID: https://pubmed.ncbi.nlm.nih.gov/27403408/. https://doi.org/10.4103/2277-9175.184277
11. Gupta S, Gyawali BR, Pradhananga RB, Rayamajhi P. Role of short course intravenous methylprednisolone in the management of sudden sensorineural hearing loss. Int J Otorhinolaryngol Head Neck Surg. 2021;7(2):217. https://doi.org/10.18203/issn.2454-5929.ijohns20210063
12. Aliyeva A, Edizer DT. Efficacy of intratympanic steroid therapy for severe and profound sudden sensorineural hearing loss. Am J Otolaryngol. 2024;45(2):104170. PMID: https://pubmed.ncbi.nlm.nih.gov/38039820/. https://doi.org/10.1016/j.amjoto.2023.104170
13. Gonzalez Fernandez A, Zapata MDC, Ruiz De Erenchun Lasa I, et al. Intratympanic steroid therapy as a salvage treatment for sudden sensorineural hearing loss after unsuccessful therapy with systemic steroids: our experience in 86 patients. Egypt J Otolaryngol. 2026;42(1):42. https://doi.org/10.1186/s43163-026-01018-2
14. Chrysouli K, Kollia P, Papanikolaou V, Chrysovergis A. The effectiveness of intratympanic steroid injection in addition to systemic corticosteroids in the treatment of idiopathic sudden sensorineural hearing loss. Am J Otolaryngol. 2023;44(4):103872. PMID: https://pubmed.ncbi.nlm.nih.gov/37130505/. https://doi.org/10.1016/j.amjoto.2023.103872
15. Sialakis C, Iliadis C, Frantzana A, Ouzounakis P, Kourkouta L. Intratympanic versus systemic steroid therapy for idiopathic sudden hearing loss: a systematic review and meta-analysis. Cureus. 2022;14(3):e22887. PMID: https://pubmed.ncbi.nlm.nih.gov/35399458/. https://doi.org/10.7759/cureus.22887
16. Sampaio AFBS, Monsanto RDC, Jorge JJ, Borges GC. Steroids for the prevention of sensorineural hearing loss secondary to acute otitis media: a systematic review. Int Arch Otorhinolaryngol. 2026;30(2):1–13. https://doi.org/10.1055/s-0045-1811640
17. Kuo LK, Wu JL, Li YL, Hsu HJ. Clinical efficacy of intratympanic steroid injection for treating idiopathic sudden sensorineural hearing loss. J Chin Med Assoc. 2024;87(3):328–333. PMID: https://pubmed.ncbi.nlm.nih.gov/38132815/. https://doi.org/10.1097/JCMA.0000000000001061
18. Tarkan Ö, Dağkıran M, Sürmelioğlu Ö, et al. Intratympanic methylprednisolone versus dexamethasone for the primary treatment of idiopathic sudden sensorineural hearing loss. J Int Adv Otol. 2018;14(3):451–455. PMID: https://pubmed.ncbi.nlm.nih.gov/30644376/. https://doi.org/10.5152/iao.2018.4871
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Sharad Paudel, Anup Acharya, Bilash Shrestha, Pratiksha Ghimire